Dawson James Securities Announces Closing of $1.75 Million Offerings with InspireMD, Inc.

BOCA RATON, FL / ACCESWIRE / March 31, 2016 / Dawson James Securities, Inc. in conjunction with InSpireMD Corporation (NYSE MKT: NSPR), announced today the closing of two separate equity offerings, with InspireMD receiving total gross proceeds of approximately $1.75 million before underwriting and other offering expenses. The Company intends to use the net proceeds from the Private Placement to conduct sales activities related to CGuard™ EPS™, and MGuard Prime™ EPS, and for general corporate purposes.

The two offerings were comprised of an underwritten public offering of 1,900,000 shares of common stock and warrants to purchase up to 950,000 shares of common stock (the Public Offering), and a separate private placement to certain of the Company’s officers and directors of up to 1,100,000 shares of its common stock and warrants to purchase up to 550,000 shares of common stock (the “Private Placement”). The common stock was priced at $0.59 per share, and the warrants for both offerings are immediately exercisable, expire in five-years and have an exercise price of $0.59 per share. Dawson James Securities Inc., acted as the sole book runner for the Public Offering, and was the Placement Agent for the Private Offering.

“InspireMD has made significant progress over the past year exemplified by its commercial launch in the European Union of its new CGuard™ product,” said Robert D. Keyser, Jr., Dawson James’ CEO. “We are pleased to assist the Company with additional growth capital as they continue their successful transition into the carotid and neurovascular interventional markets. Mr. Keyser continued, “Our strategy to utilize an effective combination of institutional investment funds along with broker-led retail investors continues to be an effective means of access to growth capital for companies like InspireMD.”

A shelf registration statement on Form S-3 declared effective by the Securities and Exchange Commission (“SEC”) on November 27, 2013, a prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC’s website located at http://www.sec.gov. A copy of the final prospectus relating to the offering may be obtained by contacting Dawson James Securities, Inc., Attention: Prospectus Department, 1 N. Federal Highway, Suite 500, Boca Raton, FL 33432, Telephone: 561-391-5555.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About INSPIREMD

InspireMD seeks to utilize its proprietary MGuard™ with MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures.

About Dawson James Securities

Dawson James Securities specializes in capital raising for small and microcap public and private growth companies primarily in the Life Science/Health Care, Technology and Consumer sectors and is a full service investment banking firm with research, institutional and retail sales, and execution trading and corporate services. Headquartered in Boca Raton, FL, Dawson James is privately held with offices in New York, California, Maryland and New Jersey. www.dawsonjames.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Member FINRA/SIPC. For more information, please contact:

Elise Stern, Managing Director, Corporate Finance
estern@dawsonjames.com
561-208-2926

SOURCE: Dawson James Securities, Inc.

ReleaseID: 438320